Niquitin Minilozenge (Nicotine)

Nicotine, the active ingredient in Niquitin Minilozenge, is a nicotine replacement therapy presented as a lozenge for oromucosal use. It helps adult smokers who wish to quit by reducing withdrawal symptoms and cravings associated with nicotine dependence.

GNH USA supplies Niquitin Minilozenge as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global market requirements. With a robust distribution network, GNH USA ensures timely delivery and supports customers with technical and regulatory assistance throughout the supply chain.

Niquitin Minilozenge, a nicotine replacement therapy, is used to support smoking cessation by addressing nicotine dependence. - Smoking cessation: assists adult smokers in quitting by reducing cravings and withdrawal symptoms. - Nicotine dependence: provides a controlled nicotine dose to alleviate physiological dependence during quit attempts. - Relapse prevention: helps maintain abstinence by managing occasional urges after initial cessation.

Niquitin Minilozenge may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Mouth irritation or soreness - Nausea or upset stomach - Hiccups - Increased salivation

Serious or Rare Side Effects: - Chest pain or cardiovascular discomfort - Severe allergic reaction (anaphylaxis) - Irregular heartbeat or arrhythmia

When using Niquitin Minilozenge, consider the following precautions: - Cardiovascular assessment: evaluate patients with heart disease before initiating therapy. - Use as part of a comprehensive quit program: combine with counseling and behavioral support. - Do not exceed recommended duration: limit use to the period advised by a healthcare professional. - Avoid use in non‑smokers and children: product is intended for adult smokers only. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Niquitin Minilozenge can interact with other medicines. Review the following interaction categories:

Major Interactions (Avoid): - Warfarin: nicotine may alter anticoagulant effect, increasing bleeding risk. - Insulin or oral hypoglycemics: nicotine can affect blood glucose control. - Beta‑blockers: nicotine may reduce therapeutic response to these agents.

Moderate Interactions (Monitor Closely): - Caffeine: concurrent use may increase stimulant effects such as jitteriness. - Certain antidepressants (e.g., SSRIs): may enhance nicotine‑related side effects. - Theophylline: nicotine can increase metabolism, potentially reducing efficacy.